Systematic overview of cochrane reviews for anticholinergic effects of antipsychotic drugs

Journal of Clinical Psychopharmacology

Volumn 29, Issue 2, 2009, Pages 141-146

  Ozbilen, Mehmet ^a   Adams, Clive E ^b  

^a SEACROFT HOSPITAL   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Anticholinergic effects; Antipsychotic drugs; Blurred vision; Constipation; Dry mouth; Schizophrenia; Trials

Indexed keywords

AMISULPRIDE; ANTIHISTAMINIC AGENT; ANTIPARKINSON AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE; CENTBUTINDOLE; CHLORAL HYDRATE; CHLORPROMAZINE; CLOCAPRAMINE; CLOZAPINE; FLUPHENAZINE; FLUSPIRILENE; HALOPERIDOL; LOXAPINE; MOPERONE; NEUROLEPTIC AGENT; OLANZAPINE; PENFLURIDOL; PERAZINE; PERPHENAZINE; PIMOZIDE; PIPOTIAZINE PALMITATE; RISPERIDONE; SULPIRIDE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE; UNINDEXED DRUG; ZOTEPINE; ZUCLOPENTHIXOL;

ANTICHOLINERGIC EFFECT; ARTICLE; BLURRED VISION; CLINICAL STUDY; CLINICAL TRIAL; CONFUSION; CONSTIPATION; CONTROLLED STUDY; HUMAN; HYPERSALIVATION; HYPERTHERMIA; INCIDENCE; NOSE CONGESTION; PREVALENCE; PRIORITY JOURNAL; SALIVATION; SCHIZOPHRENIA; SIDE EFFECT; SYSTEMATIC REVIEW; TACHYCARDIA; URINARY HESITANCY; URINE RETENTION; XEROSTOMIA;

ANTIPSYCHOTIC AGENTS; CHOLINERGIC ANTAGONISTS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REVIEW LITERATURE AS TOPIC; SCHIZOPHRENIA; VISION DISORDERS;

EID: 67649329419     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31819a91f1     Document Type: Article

References (34)

1. King D. Seminars in Clinical Psychopharmacology. 2nd ed. London, England: Gaskell (Royal College of Psychiatrists); 2004.
2. Sadock BJ, Sadock VA. Kaplan and Sadock's Comprehensive Textbook of Psychiatry, vol. 1 and 2. 8th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005.
3. Cohen DH, Sherman SM. The autonomic nervous system and its central control. In: Berne RM, Levy MN, eds. Physiology. St Louis, MO: The Mosby Company; 1988.
4. Day JC, Kinderman P, Bentall R. A comparison of patients' and prescribers' beliefs about neuroleptic side-effects: prevalence, distress and causation. Acta Psychiatr Scand. 1998;97(1):93-97.
5. Fakhoury WK, Wright D, Wallace M. Prevalence and extent of distress of adverse effects of antipsychotics among callers to a United Kingdom National Mental Health Helpline. Int Clin Psychopharmacol. 2001;16(3):153-162.
6. Beaumont G. Antipsychotics-the future of schizophrenia treatment. Curr Med Res Opin. 2000;16(1):37-42.
7. Meirik K, Linaker OM. Factors that influence self-reported compliance for neuroleptics. Eur J Psychiatry. 2001;15:5-12.
8. Misdrahi D, Llorca PM, Lancon C, et al. Compliance in schizophrenia: predictive factors, therapeutical considerations and research implications [In French]. Encephale. 2002;28(3 Pt 1): 266-272.
9. Feinberg M. The problems of anticholinergic adverse effects in older patients. Drugs Aging. 1993;3(4):335-348.
10. Lieberman JA. Managing anticholinergic side effects. Prim Care Companion J Clin Psychiatry. 2004;6(suppl 2):20-23.
11. Mintzer J, Burns A. Anticholinergic side-effects of drugs in elderly people. J R Soc Med. 2000;93(9):457-462.
12. Seifert R, Jamieson J, Gardner R Jr. Use of anticholinergics in the nursing home: an empirical study and review. Drug Intell Clin Pharm. 1983;17(6):470-473.
13. Cicero AF, Forghieri M, Cuzzola DF, et al. Extrapyramidal syndrome, anticholinergic effects and orthostatic hypotension induced by antipsychotic drugs under everyday practice condition in Italy: the PPHSS study. Rivista De Psychiatria. 2002;37(4): 184-189.
14. Barbui C, Nose M, Bindman J, et al. Sex differences in the subjective tolerability of antipsychotic drugs. J Clin Psychopharmacol. 2005;25(6):521-526.
15. Morrison P, Gaskill D, Meehan T, et al. The use of the Liverpool University Neuroleptic Side-Effect Rating Scale (LUNSERS) in clinical practice. Aust N Z J Ment Health Nurs. 2000;9(4): 166-176.
16. Banerjee S, Morgan J, Lewis M, et al. A survey of clinical care for patients with schizophrenic disorders and learning disability. J Clin Excellence. 2001;3:125-131.
17. Duggan L, Brylewski J. Antipsychotic medication versus placebo for people with both schizophrenia and learning disability. Cochrane Database Syst Rev. 2004;(4):CD000030.
18. Armitage P. Should we cross off the crossover? Br J Clin Pharmacol. 1991;32(1):1-2.
19. Wilson EB. Calculating a confidence interval of a proportion. J Am StatAssoc. 1927;22:209-212.
20. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;334:1-100.
21. Day JC, Wood G, Dewey M, et al. A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients. Br J Psychiatry. 1995;166(5):650-653.
22. Bymaster FP, Felder CC, Tzavara E, et al. Muscarinic mechanisms of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(7): 1125-1143.
23. Duggan L, Fenton M, Dardennes RM, et al. Olanzapine for schizophrenia. Cochrane Database Syst Rev. 2003;(1):CD001359.
24. Dilsaver SC. Antipsychotic agents: a review. Am Fam Physician. 1993;47(1): 199-204.
25. Coukell AJ, Spencer CM, Benfield P. Amisulpride: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia. CNS Drugs. 1996;6:237-256.
26. Schoemaker H, Claustre Y, Fage D, et al. Neurochemical characteristic of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther. 1997;280:83-97.
27. Waddington JL, Scully PJ, O'Callaghan E. The new antipsychotics, and their potential for early intervention in schizophrenia. Schizophr Res. 1997;28(2-3):207-222.
28. Knable MB, Heinz A, Raedler T, et al. Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels. Psychiatry Res. 1997;75(2):91-101.
29. Lavalaye J, Booij J, Linszen DH, et al. Higher occupancy of muscarinic receptors by olanzapine than risperidone in patients with schizophrenia. A[123I]-IDEX SPECT study. Psychopharmacology (Berl). 2001;156(1):53-57.
30. De Leon J, Odom-White A, Josiassen RC, et al. Serum antimuscarinic activity during clozapine treatment. J Clin Psychopharmacol. 2003; 23(4):336-341.
31. Sethy VH, Ellerbrock BR, Wu H. Comparative dopaminergic and muscarinic antagonist activity of clozapine and haloperidol. Life Sci. 1996;58(7):585-590.
32. Lawrie SM, McIntosh AM, Rao S. Critical Appraisal for Psychiatry. Edinburgh, Scotland: Churchill Livingstone; 2000.
33. Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N EnglJ Med. 2005;353(12):1209-1223.
34. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006;63(10):1079-1087.